Ho Seung Lee, Tae Jun Song, Sung Hyun Cho, Gunn Huh, Dongwook Oh, Jae Min Lee, Jae Hoon Lee, Dae Wook Hwang, Dong-Wan Seo
{"title":"门静脉栓塞后不可切除胆管癌患者的预后:倾向评分匹配分析。","authors":"Ho Seung Lee, Tae Jun Song, Sung Hyun Cho, Gunn Huh, Dongwook Oh, Jae Min Lee, Jae Hoon Lee, Dae Wook Hwang, Dong-Wan Seo","doi":"10.1002/jhbp.12192","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the outcomes of patients with unresectable cholangiocarcinoma (CCA) who underwent portal vein embolization (PVE) with a focus on overall survival (OS) and the frequency of biliary drainage (BD).</p><p><strong>Methods: </strong>In this retrospective analysis, we evaluated 255 patients with unresectable CCA; 56 patients underwent PVE but ultimately remained unresectable. Propensity score matching (PSM) was used to minimize the potential confounding factors. The primary outcome was the OS, while the secondary outcome was BD frequency.</p><p><strong>Results: </strong>The PVE-unresectable group showed lower OS than that in the non-PVE-unresectable group both before and after PSM (median OS: 238.5 vs. 371.0 days, p = 0.006; 238.5 vs. 483.5 days, p = 0.002, respectively). Unresectable PVE status was a predictor of worse survival both before and after PSM (hazard ratio [HR] = 2.06, p < 0.001 and HR = 2.46, p < 0.001, respectively). Chemotherapy improved survival before and after PSM (HR = 0.45, p < 0.001 and HR = 0.41, p = 0.003, respectively). The BD frequency was higher in the PVE-unresectable group than in the non-PVE-unresectable group before and after PSM (0.693 vs. 0.470 procedures per month, p = 0.010).</p><p><strong>Conclusions: </strong>Patients with unresectable CCA who underwent PVE had worse survival outcomes and required BD. Optimizing systemic therapy and BD strategies may improve the outcomes.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of Patients With Unresectable Cholangiocarcinoma After Portal Vein Embolization: A Propensity Score-Matched Analysis.\",\"authors\":\"Ho Seung Lee, Tae Jun Song, Sung Hyun Cho, Gunn Huh, Dongwook Oh, Jae Min Lee, Jae Hoon Lee, Dae Wook Hwang, Dong-Wan Seo\",\"doi\":\"10.1002/jhbp.12192\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>This study aimed to evaluate the outcomes of patients with unresectable cholangiocarcinoma (CCA) who underwent portal vein embolization (PVE) with a focus on overall survival (OS) and the frequency of biliary drainage (BD).</p><p><strong>Methods: </strong>In this retrospective analysis, we evaluated 255 patients with unresectable CCA; 56 patients underwent PVE but ultimately remained unresectable. Propensity score matching (PSM) was used to minimize the potential confounding factors. The primary outcome was the OS, while the secondary outcome was BD frequency.</p><p><strong>Results: </strong>The PVE-unresectable group showed lower OS than that in the non-PVE-unresectable group both before and after PSM (median OS: 238.5 vs. 371.0 days, p = 0.006; 238.5 vs. 483.5 days, p = 0.002, respectively). Unresectable PVE status was a predictor of worse survival both before and after PSM (hazard ratio [HR] = 2.06, p < 0.001 and HR = 2.46, p < 0.001, respectively). Chemotherapy improved survival before and after PSM (HR = 0.45, p < 0.001 and HR = 0.41, p = 0.003, respectively). The BD frequency was higher in the PVE-unresectable group than in the non-PVE-unresectable group before and after PSM (0.693 vs. 0.470 procedures per month, p = 0.010).</p><p><strong>Conclusions: </strong>Patients with unresectable CCA who underwent PVE had worse survival outcomes and required BD. Optimizing systemic therapy and BD strategies may improve the outcomes.</p>\",\"PeriodicalId\":16056,\"journal\":{\"name\":\"Journal of Hepato‐Biliary‐Pancreatic Sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepato‐Biliary‐Pancreatic Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/jhbp.12192\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepato‐Biliary‐Pancreatic Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jhbp.12192","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:本研究旨在评估不可切除胆管癌(CCA)患者行门静脉栓塞(PVE)的预后,重点关注总生存期(OS)和胆道引流(BD)频率。方法:回顾性分析255例不能切除的CCA患者;56例患者接受了PVE,但最终仍无法切除。倾向评分匹配(PSM)被用来最小化潜在的混杂因素。主要终点为OS,次要终点为BD频率。结果:pve -不可切除组在PSM前后的OS均低于非pve -不可切除组(中位OS: 238.5 vs. 371.0天,p = 0.006;238.5 vs 483.5天,p = 0.002)。不可切除的PVE状态是PSM前后较差生存的预测因子(危险比[HR] = 2.06, p)。结论:不可切除的CCA患者接受PVE后生存结果较差,需要BD治疗。优化全身治疗和BD策略可能改善预后。
Outcomes of Patients With Unresectable Cholangiocarcinoma After Portal Vein Embolization: A Propensity Score-Matched Analysis.
Background: This study aimed to evaluate the outcomes of patients with unresectable cholangiocarcinoma (CCA) who underwent portal vein embolization (PVE) with a focus on overall survival (OS) and the frequency of biliary drainage (BD).
Methods: In this retrospective analysis, we evaluated 255 patients with unresectable CCA; 56 patients underwent PVE but ultimately remained unresectable. Propensity score matching (PSM) was used to minimize the potential confounding factors. The primary outcome was the OS, while the secondary outcome was BD frequency.
Results: The PVE-unresectable group showed lower OS than that in the non-PVE-unresectable group both before and after PSM (median OS: 238.5 vs. 371.0 days, p = 0.006; 238.5 vs. 483.5 days, p = 0.002, respectively). Unresectable PVE status was a predictor of worse survival both before and after PSM (hazard ratio [HR] = 2.06, p < 0.001 and HR = 2.46, p < 0.001, respectively). Chemotherapy improved survival before and after PSM (HR = 0.45, p < 0.001 and HR = 0.41, p = 0.003, respectively). The BD frequency was higher in the PVE-unresectable group than in the non-PVE-unresectable group before and after PSM (0.693 vs. 0.470 procedures per month, p = 0.010).
Conclusions: Patients with unresectable CCA who underwent PVE had worse survival outcomes and required BD. Optimizing systemic therapy and BD strategies may improve the outcomes.
期刊介绍:
The Journal of Hepato-Biliary-Pancreatic Sciences (JHBPS) is the leading peer-reviewed journal in the field of hepato-biliary-pancreatic sciences. JHBPS publishes articles dealing with clinical research as well as translational research on all aspects of this field. Coverage includes Original Article, Review Article, Images of Interest, Rapid Communication and an announcement section. Letters to the Editor and comments on the journal’s policies or content are also included. JHBPS welcomes submissions from surgeons, physicians, endoscopists, radiologists, oncologists, and pathologists.